Objective The epithelial to mesenchymal transition (EMT) is associated with acquired
resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in …

Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …

Introduction: Dual inhibition of SRC-and EGFR-dependent pathways may overcome
acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …

EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of
treatment with EGFR-inhibitors, such as erlotinib. Multiple resistance mechanisms have …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the standard
therapy for non-small cell lung cancer (NSCLC) harboring EGFR mutations, but the …

Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients
initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several …

Introduction Mesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in
non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations. In …

Background The first‐line standard treatment of non‐small cell lung cancer (NSCLC) with
EGFR mutation is EGFR‐tyrosine kinase inhibitors (TKIs). However, most patients will …

We report the first case of epithelial-to-mesenchymal transition (EMT) as the cause of
acquired resistance to the second-generation EGFR-tyrosine kinase inhibitor (TKI), afatinib …